Submission of Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals' board, meeting on 24 December 2025, approved the allotment of 10,74,000 equity shares at Rs. 20 each (face value Rs. 10, premium Rs. 10) to 4 allottees upon conversion of warrants. These warrants were originally issued on 10 January 2025 on a preferential basis to promoter and non-promoter categories. The company received Rs. 1.61 crore, representing the remaining 75% of the issue price. As a result, the paid-up equity capital has increased from Rs. 16.14 crore to Rs. 17.215 crore, with total equity shares rising from 1,61,41,000 to 1,72,15,000. This is part of a larger warrant issuance of 1,50,00,000 warrants, of which around 73.9 lakh have been converted so far.
This is a routine warrant-to-equity conversion that expands the share base by about 6.7% and brings in Rs. 1.61 crore to the company. Minor dilution for existing shareholders, but no major price-moving event as the conversion price was already pre-set at Rs. 20.